BidaskClub Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday, January 9th.

A number of other research firms have also recently issued reports on COLL. Piper Jaffray Companies set a $23.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, December 14th. Needham & Company LLC lifted their price target on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group raised their price objective on Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 5th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Monday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average target price of $23.33.

Collegium Pharmaceutical (NASDAQ COLL) traded down $0.15 during trading on Tuesday, reaching $20.98. 571,630 shares of the company were exchanged, compared to its average volume of 476,573. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $21.50. The firm has a market cap of $685.44 and a PE ratio of -7.06.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. During the same quarter last year, the company earned ($1.13) EPS. The firm’s revenue for the quarter was up 2814.6% compared to the same quarter last year. sell-side analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.

In other news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, December 8th. The stock was sold at an average price of $17.34, for a total transaction of $17,340,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael Thomas Heffernan sold 50,000 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the transaction, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Insiders sold a total of 1,065,558 shares of company stock worth $18,396,477 in the last 90 days. 25.76% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pura Vida Investments LLC purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth $1,229,000. Teton Advisors Inc. purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth $283,000. Bank of New York Mellon Corp raised its holdings in shares of Collegium Pharmaceutical by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after acquiring an additional 39,656 shares during the period. Teachers Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 98.8% during the 2nd quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock worth $745,000 after acquiring an additional 29,617 shares during the period. Finally, Macquarie Group Ltd. raised its holdings in shares of Collegium Pharmaceutical by 18.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock worth $13,951,000 after acquiring an additional 211,288 shares during the period. Institutional investors and hedge funds own 79.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/01/17/collegium-pharmaceutical-coll-lowered-to-buy-at-bidaskclub.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply